BLCO (Bausch & Lomb) Total Equity: $6,452 Mil (As of Mar. 2026)


BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $16.29
GF Value $18.37
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Bausch & Lomb Total Equity?

Bausch & Lomb BLCO -0.18% 77 Total Equity is $6,452 Mil as of Mar. 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.37 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Bausch & Lomb's total equity for the quarter that ended in Mar. 2026 was $6,452 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bausch & Lomb Total Equity Historical Data

* Premium members only.

The historical data trend for Bausch & Lomb's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch & Lomb Total Equity Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 9,402.00 7,101.00 6,920.00 6,544.00 6,519.00

Bausch & Lomb Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,433.00 6,508.00 6,500.00 6,519.00 6,452.00
BLCO
77GF Score
Bausch & Lomb Corp BLCO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch & Lomb Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bausch & Lomb's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=14022-7503
=6,519

Bausch & Lomb's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=13780-7328
=6,452

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $6,452 Mil mean?
Bausch & Lomb (BLCO) has a Total Equity of $6,452 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Bausch & Lomb and its competitors.
Is Bausch & Lomb's Total Equity too high?
Bausch & Lomb's current Total Equity is $6,452 Mil. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Total Equity compare to ISRG and BDX?
Bausch & Lomb's Total Equity of $6,452 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Bausch & Lomb and its competitors. Bausch & Lomb's current Total Equity is $6,452 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.37, compared to a current price of $16.29 — trading 11.3% below its estimated fair value. The current Total Equity is $6,452 Mil. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Total Equity is $6,452 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $16.29 is trading 11.3% below its estimated GF Value™ of $18.37. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

  • Total Equity: $6,452 Mil
  • GF Value™: $18.37 vs. price of $16.29 (11.3% below fair value)
  • GF Score™: 77/100 with 9 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.29
Price
$18.37
GF Value